Skip to main content

NIH to Fund 12 Groups with $150M in Total As Part of Renewed PGx Research Network

NEW YORK, Sept. 28 (GenomeWeb News) - The National Institutes of Health will fund 12 groups with more than $150 million over five years in total under its renewed Pharmacogenetics Research Network, the NIH said today.


Originally, the initiative, led by the National Institute of General Medical Sciences and eight other NIH institutes, was funded from 2000 to 2005.


The following groups will receive funding:


-         The Pharmacogenetics and Pharmacogenomics Knowledge Base, headed by Russ Altman at Standford University School of Medicine, will receive $13.7 million;


-         Pharmacogenetics of Nicotine Addiction and Treatment, headed by Neal Benowitz at UCSF, will receive $10 million;


-         The Consortium on Breast Cancer Pharmacogenomics, headed by David Flockhart at Indiana University School of Medicine, will receive $11.6 million;


-         Pharmacogenetics of Membrane Transporters, headed by Kathleen Giacomini at UCSF, will receive $15 million;


-         Pharmacogenomic Evaluation of Antihypertensive Responses, headed by Julie Johnson at the University of Florida, Gainesville, will receive $11.1 million;


-         Pharmacogenetics and Risk of Cardiovascular Disease, headed by Ronald Krauss at UC Berkeley/Lawrence Berkeley National Laboratory, will receive $14.8 million;


-         Functional Polymorphism Analysis in Drug Pathways, headed by Howard McLeod at Washington University, will receive $10.5 million;


-         Pharmacogenetics of Anticancer Agents, headed by Mark Ratain at the University of Chicago and Mary Relling at St. Jude Children's Hospital, will receive $14.9 million;


-         Pharmacogenomics of Arrhythmia Therapy, headed by Dan Roden at Vanderbilt University, will receive $14 million;


-         The Amish Pharmacogenomics of Antiplatelet Intervention Study, headed by Alan Shuldiner at the University of Maryland School of Medicine, will receive $7.5 million;


-         Pharmacogenetics of Phase II Drug Metabolizing Enzymes, headed by Richard Weinshilboum at the Mayo Clinic College of Medicine, will receive $12.6 million;


-         Pharmacogenetics of Asthma Treatment, headed by Scott Weiss at Brigham and Women's Hospital and Harvard Medical School, will receive $16.8 million.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.